Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL13298786 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4619759 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896653 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL142573 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL10028910 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12269503 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL13061461 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL9015606 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115010915-A | Nitrogen branched nine-arm polyethylene glycol derivative, preparation method and biological related substance modified by nitrogen branched nine-arm polyethylene glycol derivative | 厦门赛诺邦格生物科技股份有限公司 | 2022-09-06 | — | — | CN | claimed |
| US-11407768-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-08-09 | — | — | US | claimed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | claimed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-112694608-A | Six-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2021-04-23 | — | — | CN | claimed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106967213-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2019-11-05 | — | — | CN | claimed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | claimed |
| CN-104877127-B | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification | 厦门赛诺邦格生物科技股份有限公司 | 2017-11-10 | — | — | CN | claimed |
| US-20010049443-A1 | Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2001-12-06 | — | — | US | claimed |
| WO-2001074776-A1 | PROCESS FOR THE PREPARATION OF 1,5-DIDEOXY-1,5-IMINO HEXITOLS FROM OXIMES OR IMINES | MICHIGAN STATE UNIVERSITY (US) | 2001-10-11 | — | — | WO | claimed |
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | claimed |
| US-4339585-A | Method for the production of 2-hydroxymethyl-3,4,5-trihydroxy piperidine and the corresponding N-methyl derivative | NIPPON SHINYAKU CO., LTD. (JP) | 1982-07-13 | — | — | US | claimed |
| US-RE30886-E | AND INHIBITING LIPID SYNTHESIS, USING 2-HYDROXYMETHYL-3,4,5-TRIHYDROXY-PIPERIDINE | NIPPON SHINYAKU COMPANY LTD. (JP) | 1982-03-23 | — | — | US | claimed |
| US-4312872-A | TREATMENT OF ADIPOSITY, DIABETES, AND HYPERLIPOPROTEINEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-26 | — | — | US | claimed |
| US-4198481-A | CULTURING STRAIN OF STREPTOMYCES | NIPPON SHINYAKU CO., LTD. (JP) | 1980-04-15 | — | — | US | claimed |
| US-4137231-A | Process for the isolation of 2-hydroxymethyl-3,4,5-trihydroxypiperidine from plant material | NIPPON SHINYAKU CO., LTD. (JP) | 1979-01-30 | — | — | US | claimed |
| US-4065562-A | 2-HYDROXYMETHYL-3,4,5-TRIHYDROXY-PIPERIDINE | NIPPON SHINYAKU CO., LTD. (JA) | 1977-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049443-A1 | Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines | GALE, HK1, G6PD | GAA 914/4885GLA 349/4885FUCA1 1053/4885 |
| US-11407768-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAA1 | GAA 784/4885GLA 1300/4885FUCA1 974/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | GAA 1797/4885GLA 1838/4885FUCA1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.